title: Choroidal thickness and visual prognosis in type 1 lesion due to neovascular age-related macular degeneration.
abstract: OBJECTIVE
  To evaluate the association between subfoveal choroidal thickness and the visual outcome in eyes with type 1 choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD).
  
  
  METHODS
  This was a retrospective, longitudinal, cross-sectional study including patients diagnosed with nAMD type 1 lesions managed with intravitreal injections of ranibizumab in a PRN strategy during 24 months. Retrospective chart review of patients with type 1 CNV recording the visual acuity, number of intravitreal injections, multimodal imaging data, and follow-up period was performed. Subfoveal choroidal thickness was measured using enhanced depth imaging scans obtained with spectral-domain optical coherence tomography.
  
  
  RESULTS
  Twenty-five eyes of 21 patients were included. The mean baseline logMAR best-corrected visual acuity was 0.52 (+0.35) (median 0.5; range 0.1-1; interquartile range (IQR) 0.3-0.8) and improved to 0.39 (+0.39) (median 0.4; range 0.1-1; IQR 0.2-0.5) by the end of the follow-up (p = 0.038). Subfoveal choroidal thickness was 202.8 (+60.3) μm (median 218; range 81-285; IQR 146-258). Statistical mixed effects model demonstrated an association between rate of improvement of visual acuity with subfoveal choroidal thickness after 24 months (p<0.001) (95% confidence interval 0.0002-0.0001 logMAR month μm); higher thickness values were correlated with better visual acuity.
  
  
  CONCLUSIONS
  Thicker subfoveal choroid was associated with better visual outcomes in patients with type 1 CNV due to nAMD following a strict PRN regimen with intravitreal ranibizumab at 24 months of follow-up.
authors.affiliation:  Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia - Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: Hernández-Martínez
authors.affiliation:  Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia - Spain.| RETICS Oftared, Instituto de Salud Carlos III, Madrid - Spain.
authors.forename: Rosa
authors.initials: R
authors.lastname: Dolz-Marco
authors.affiliation:  Biostatistics Unit, Health Research Institute La Fe, Valencia - Spain.
authors.forename: David
authors.initials: D
authors.lastname: Hervás-Marín
authors.affiliation:  Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia - Spain.| RETICS Oftared, Instituto de Salud Carlos III, Madrid - Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: Andreu-Fenoll
authors.affiliation:  Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia - Spain.| RETICS Oftared, Instituto de Salud Carlos III, Madrid - Spain.
authors.forename: Roberto
authors.initials: R
authors.lastname: Gallego-Pinazo
authors.affiliation:  Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD - USA.
authors.forename: José Fernando
authors.initials: JF
authors.lastname: Arévalo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002829:Choroid / Q000473:pathology*; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology / Q000473:pathology* / Q000503:physiopathology; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D016014:Linear Models; D008137:Longitudinal Studies; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D011379:Prognosis; D000069579:Ranibizumab / Q000627:therapeutic use; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab